ASSOCIATION OF SERUM HOMOCYSTEINE IN DIABETIC NEUROPATHY
DOI:
https://doi.org/10.22159/ajpcr.2018.v11s4.31741Keywords:
Diabetes, Diabetic neuropathy, Homocysteine, Hyperhomocysteinemia, MethionineAbstract
Aims and Objectives: The main aim of the study was to find out the association of serum homocysteine (HCY) in diabetic neuropathy patients.
Methods: All the patients who were diagnosed with Type II diabetes mellitus will be included. Their serum levels of fasting blood sugar, postprandial blood sugar, glycated hemoglobin, and associated blood parameters will be assessed. Diabetic neuropathy will be confirmed using nerve conduction testing, electromyography, and quantitative sensory testing with clinically correlated. The serum HCY levels will be measured and correlated with other blood parameters.
Results: Of 1000 patients, 46 were Type I diabetic and 954 were Type II. The prevalence of neuropathy in diabetic patients was 156. Mean serum HCY without diabetic neuropathy was 6.8+2.9 and serum HCY with diabetic neuropathy was 21.6+0.29 and p value was found to be 0.0017. The correlation between serum HCY and diabetic neuropathy was found to be 14.5 with p=0.001.
Conclusion: There has been a significant increase of HCY in diabetic patients. It can be clearly seen that elevated serum HCY level has led to some of the complications of diabetic neuropathy.
Downloads
References
Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: A review of current trends. Oman Med J 2012;27:269-73.
Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia 2000;43:957-73.
Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: Mechanisms to management. Pharmacol Ther 2008;120:1-34.
Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: Clinical manifestations and current treatments. Lancet Neurol 2012;11:521-34.
Nygård O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, et al. Total plasma homocysteine and cardiovascular risk profile. The hordaland homocysteine study. JAMA 1995;274:1526-33.
Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutr J 2015;14:6.
Ferri FF, editor. Laboratory Tests and Interpretation of Results. Ferri’s Clinical Advisor. 1st ed. Philadelphia, PA: Elsevier Mosby; 2012.
Ansari R, Mahta A, Mallack E, Luo JJ. Hyperhomocysteinemia and neurologic disorders: A review. J Clin Neurol 2014;10:281-8.
Pirouzpanah S, Taleban FA, Mehdipour P, Atri M, Foroutan-Ghaznavi M. Plasma total homocysteine level in association with folate, pyridoxine, and cobalamin status among iranian primary breast cancer patients. Nutr Cancer 2014;66:1097-108.
Brattström L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine: Determinants of plasma levels in middle-aged and elderly subjects. J Intern Med 1994;236:633-41.
Arnesen E, Refsum H, Bønaa KH, Ueland PM, Førde OH, Nordrehaug JE, et al. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704-9.
Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease: Causal or casual? Arch Intern Med 2000;160:422-34.
Anand P, Awasthi S, Mahdi A, Tiwari M, Agarwal GG. Serum homocysteine in Indian adolescents. Indian J Pediatr 2009;76:705-9.
Januła A, Rujaswini T. Homocysteine and diabetes. Warsaw, Poland: Wiadomosci lekarskie; 1960. p. 58-6.
Jacob S. Homocysteine metabolism. Ann Rev Nutr 1999;19:217-46.
Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 2005;3:1646-54.
Fokkema MR, Gilissen MF, Van Doormaal JJ, Volmer M, Kema IP, Muskiet FA, et al. Fasting vs nonfasting plasma homocysteine concentrations for diagnosis of hyperhomocysteinemia. Clin Chem 2003;49:818-21.
Chowdary PR, Praveen D, Aanandhi MV. A prospective study on incidence of dyslipidemia in diabetes mellitus. Res J Pharm Tech 2017;10:431-3.
Fotiou P, Raptis A, Apergis G, Dimitriadis G, Vergados I, Theodossiadis P, et al. Vitamin status as a determinant of serum homocysteine concentration in Type 2 diabetic retinopathy. J Diabetes Res 2014;2014:807209.
Lakshman R, Negi NS, Gupta B. Prevalence of hyperhomocysteinaemia in Type 2 diabetes mellitus and its correlation with its complications. J Ind Aca Clin Med 2012;13:277-81.
Saurabh B, Kapoor SG. Serum homocysteine levels in Type 2 diabetes mellitus patients. 2015;2015:77-83.
Ambrosch A, Dierkes J, Lobmann R, Kühne W, König W, Luley C, et al. Relation between homocysteinaemia and diabetic neuropathy in patients with Type 2 diabetes mellitus. Diabet Med 2001;18:185-92.
Buysschaert M, Dramais AS, Wallemacq PE, Hermans MP. Hyperhomocysteinemia in Type 2 diabetes: Relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 2000;23:1816-22.
Heming G, Chen X, Zhang H, Zhang X. Serum homocysteine levels and diabetic neuropathy in patients with Type 2 diabetes mellitus: A systematic review and meta-analysis. Int J Clin Exp Med 2016;9:19588-94.
Brazionis L, Rowley K Sr, Itsiopoulos C, Harper CA, O’Dea K. Homocysteine and diabetic retinopathy. Diabetes Care 2008;31:50-6.
Alnajjar MK. Homocysteine Levels and Some Biochemical Parameters Among Type 2 Diabetic Nephropathy Patients. Gaza City: Doctoral dissertation, Islamic University-Gaza; 2013.
Mundu PA, Kumar B, Mitra JK, Kumar M, Sinha R. Study of Assessment of Plasma Homocysteine Level in Microvascular Complications of Type 2 Diabetes Mellitus; 2017.
Hammad RS. Homocysteine and Some Biochemical Parameters in Type 2 Diabetic Patients from Gaza Governorate. Gaza: Islamic
University-Gaza. Faculty of Science. Medical Technology; 2013.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
